Table I. Differentially expressed proteins and their relative abundance in 48 hours after treatment (in parentheses). FDR-corrected p values (q-values) <0.05 were used to select differentially expressed proteins. Presented proteins have treated/conrol ratios outside the range of two standard deviations from the mean (0.72–1.30).
| Positive control proteins |
Metabolic proteins |
|||
|---|---|---|---|---|
| Up-regulated | Down-regulated | Up-regulated | Down-regulated | |
| High-galactose-no-glucose media | SLC2A1 (2.0) | ALDOC (1.7) | ||
| HSPA5 (1.7) | ||||
| HYOU1 (1.4) | ||||
| Hypoxia | SLC2A1 (3.0)a | PGR (0.5) | ALDOC (3.1)a | FBP2 (0.7) |
| GREB1 (0.6) | GPI (1.9) | |||
| LDHA (1.9)a | ||||
| PGK1 (1.8)a | ||||
| PFKP (1.7)a | ||||
| SLC7A5 (1.7) | ||||
| ALDOA (1.5)a | ||||
| SDHA (1.5) | ||||
| PKM1/M2 (1.4)a | ||||
| GAPDH (1.4)a | ||||
| ENO1 (1.3)a | ||||
| PGAM1 (1.3)a | ||||
| Estradiol stimulation | TFF1 (5.7)b | SLC1A5 (1.4) | FBP1 (0.6)b | |
| PGR (4.1)b | FBP2 (0.6)b | |||
| GREB1 (4.1)b | ||||
| TFRC (3.1) | ||||
| TPD52L1 (2.8)b | ||||
| MCF-10A | GLUD1 (5.4) | TFF1 (0.01) | ||
| LDHA (4.9) | FBP1 (0.01) | |||
| SDHB (3.2) | FBP2 (0.1) | |||
| UGP2 (2.8) | IDH2 (0.1) | |||
| FH (2.4) | G6PD (0.1) | |||
| PGM2 (2.2) | GALK1(0.1) | |||
| HK1 (2.2) | GREB1 (0.2) | |||
| TUBB2C (1.9) | TPD52L1 (0.2) | |||
| IDH3G (1.9) | SLC1A5 (0.2) | |||
| PDHA1 (1.9) | PES1 (0.2) | |||
| PDHB (1.8) | TFRC (0.3) | |||
| TUBB (1.7) | PCK2 (0.3) | |||
| ACO2 (1.7) | PFKL (0.3) | |||
| SUCLA2 (1.7) | RPIA (0.3) | |||
| DLAT (1.6) | ALDOC (0.4) | |||
| PGD (0.4) | ||||
| HSP90AB1 (0.5) | ||||
| HYOU1 (0.5) | ||||
| PGR (0.5) | ||||
| GAPDH (0.6) | ||||
| RPL6 (0.6) | ||||
| SUCLG2 (0.6) | ||||
| ALDOA (0.7) | ||||
| RPL27A (0.7) | ||||
a Promoters or enhancers of these genes have hypoxia-responsive elements (HRE).
b Promoters or enhancers of these genes have estrogen-responsive elements (ERE).